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pamidronate given at transplantation and one month later. ThePamidronate therapy as prevention of bone loss following renal
regimen was simple to administer, well tolerated and poten-transplantation.
tially applicable to other clinical groups of glucocorticoid treat-Background. Very rapid bone loss, osteopenia and skeletal
ment patients.morbidity after renal transplantation have been well docu-
mented and found to occur in a sex dependent fashion. Gluco-
corticoids, cyclosporine and pre-existing uremic osteodystro-
phy have been implicated in the pathogenesis of the skeletal Renal transplantation is associated with marked skele-lesions. Glucocorticoid induced osteopenia is also a serious
tal morbidity. Osteopenia is frequent and the fractureclinical problem in patients with various nonrenal diseases and
risk is increased [1]. This appears likely to be the resultcan be prevented, or at least attenuated, by pamidronate and
other bisphosphonates. both of unresolved abnormalities of bone and mineral
Method. We prospectively studied 26 male patients under- metabolism related to previous uremia (residual hyper-
going renal transplantation, and randomized them to receive parathyroidism, low turnover or high turnover osteodys-either placebo or intravenous pamidronate (0.5 mg/kg) at the
trophy) and also of new deleterious consequences oftime of transplantation and again one month later. All patients
transplantation and its treatment. Dalen and Alvestrandreceived immunosuppression comprising prednisolone, cyclos-
porine and azathioprine. The bone mineral density (BMD) of found accelerated bone loss following transplantation
the second, third and fourth lumbar vertebrae and of the femo- [2], and Julian et al [3] while confirming rapid early bone
ral neck was measured at the time of transplantation and at loss, also demonstrated that the histological changes seen
three months and 12 months after transplantation using dual
in bone six months after transplantation were consistentenergy X-ray absorptiometry (DXA).
with the toxic effects of glucocorticoids.Results. Twelve months after transplantation, the mean (6
SEM) BMD of the lumbar vertebrae in patients who received We have previously shown that the rapid bone loss
placebo had decreased 6.4% (P , 0.05). In contrast, patients during the first year after renal transplantation occurred
who received pamidronate experienced no significant reduc- in a sex dependent fashion: females lost bone mainly
tion of BMD at the lumbar vertebrae. At the femoral neck,
from the lumbar spine and males from the femoral neckplacebo-treated patients showed a reduction of BMD of 9%
[4]. These studies and others [2, 3, 5] have shown that(P , 0.005), whereas there was no significant change in the
bone loss during the first six months occurs at a verypamidronate treated group. The two study groups had similar
patient profiles, serum parathyroid hormone (PTH) and alu- high rate, with subsequent slowing and in some cases
minium concentrations. After transplantation, comparable falls stabilization of bone density [6]. Glucocorticoids and
in the serum creatinine and PTH concentration were found in cyclosporine are thought to be implicated, although thethe two groups. Apart from transient hypocalcemia in two pa-
role of the latter is controversial [7, 8]. Whereas cyclospo-tients, no significant adverse effects of pamidronate were noted.
rine was shown to increase bone remodeling in someConclusion. This study has shown that the early rapid bone
loss that occurs in men during the first 12 months after renal animal models, and thereby lead to a high remodeling
transplantation can be prevented by two intravenous doses of osteopenia with accelerated resorption [9], bone resorp-
tion in vitro is inhibited by cyclosporine [10]. Glucocorti-
coids inhibit intestinal calcium absorption [11], increase
1 See Editorial, p. 735 calciuria (with resulting subtle hyperparathyroidism) and
reduce the secretion of sex hormones [12, 13]. Glucocor-Key words: transplantation, osteoporosis, bisphosphonates, pamidro-
nate, renal, control trial ticoids also have direct and complex effects on bone
metabolism [14] with clear-cut osteoblast toxicity andReceived for publication December 22, 1998
enhanced resorptive responsiveness to parathyroid hor-and in revised form August 2, 1999
Accepted for publication September 28, 1999 mone (PTH) [15, 16]. Thus, the renal transplant recipient
faces a formidable array of risk factors for bone loss.Ó 2000 by the International Society of Nephrology
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Table 1. Clinical details ceived placebo (500 mL 0.9% saline) at the same time
points. Both groups received standard immunosuppres-Pamidronate Control
sion with cyclosporine, azathioprine and prednisoloneNumber of patients 14 12
Age (range) 53 (23–66) 50 (23–74) (Table 3). Episodes of renal dysfunction were managed
Modality hemodialysis: CAPD 7:7 5:7 conventionally by renal biopsy and treatment of rejec-
Time on dialysis years 5.5 4.75
tion with either three 500 mg doses of methylpredniso-Number with diabetes mellitus 2 0
Etiology of renal failure lone or a 10 day course of anti-thymocyte globulin (Me-
Chronic glomerulonephritis 1 3 rieux Transplant Ltd., Maidenhead, UK).Polycystic kidneys 6 4
Dual energy X-ray absorptiometry (DXA) was per-Diabetic nephropathy 2 0
Hypertension 1 2 formed in the first week after transplantation, at three
Vasculitis 1 1 months and at one year. Serum intact PTH concentra-Dysplastic kidneys 1 0
tions were measured preoperatively and 12 months post-Unknown/others 2 2
operatively. Serum aluminium concentrations were mea-
sured preoperatively. Routine blood chemistry including
calcium and phosphate was monitored daily for two
On the background, we have now studied the impact weeks, and thereafter at a frequency dictated by clinical
of anti-resorptive therapy given in the immediate post- events.
transplant phase. In the knowledge that bisphosphonates
have been found to be effective in the treatment of gluco- Laboratory measurements
corticoid induced osteopenia in patients without renal Parathyroid hormone was measured by a two site ra-
disease [17], we have now evaluated the ability of pami- dioimmunoassay for intact PTH (Diagnostic Product
dronate to prevent the early bone loss following renal Corp., Los Angeles, CA, USA). The normal range for
transplantation. Pamidronate has been used in patients this assay is 10 to 65 pg/ml, with intra-assay and interassay
with renal failure who have hypercalcemia secondary to coefficient of variations (CV) ,7% over the range of 10
malignancy [18, 19], and it has also been shown to be to 1000 pg/ml. Routine blood chemistry including cal-
effective at preventing bone loss in patients receiving glu- cium (adjusted for serum albumin [22]), phosphate and
cocorticoids for respiratory [20] and rheumatological [21] alkaline phosphatase was measured in serum using a
diseases. In the absence of data on the use of pamidronate DAX autoanalyzer (Bayer Diagnostics, Basingstoke, UK).
in the immediate post-transplant period, we selected a Plasma cyclosporine levels were measured by a mono-
dose in the lower range of that used to treat hypercalce-
clonal cyclosporine specific radioimmunoassay (Incstar,
mia due to malignancy. Our previous finding of marked
Stillwater, MN, USA), with inter assay and intra-assaysex differences in the pattern of bone loss in this setting
CVs of 7 to 10%. Serum aluminium was measured by[4] led us to study one sex only, in this case, men.
flameless atomic absorption spectrometry [23].
Bone densitometryMETHODS
Dual energy X-ray absoptometry (DXA) was per-Subjects
formed using a Lunar DPX scanner (Lunar RadiationWe studied 26 male patients admitted for cadaveric
Corp., Madison, WI, USA). We measured bone mineralkidney transplantation. The study was approved by the
density (BMD) at the second, third and fourth lumbarlocal institutional review body and all patients provided
vertebrae in the anterior-posterior projection (L2-4), andwritten informed consent before the start of the study.
at the femoral neck. The in-house precision of theseThe patients were randomized to receive either pamidro-
measurements was ,2% for all indices. BMD was ex-nate (14 patients) or placebo (12 patients).
pressed in g/cm2, calibrated against calcium hydroxyapa-The details of the enrolled patients are summarized
tite, and the reproducibility of repeated measurementsin Tables 1 and 2. The patients in the two groups were
using the machine was also ,2%. The scans were per-comparable with respect to age, duration of previous
formed by a single operator throughout the study. Thedialysis, previous transplant history and pretransplant
results were compared with the UK reference databasebiochemistry, including PTH, total alkaline phosphatase,
(age/sex-matched) to generate a T score.serum aluminium, calcium and phosphorous.
Statistical analysisStudy protocol
Paired Student’s t-tests (two tailed) were used to com-Patients were randomized individually to one of two
pare intragroup changes of the regional BMD. Regres-groups. One group received pamidronate (0.5 mg/kg in
sion analysis was used to relate serum PTH and alumin-500 mL 0.9% saline intravenously preoperatively and
again 1 month postoperatively) and the other group re- ium concentrations to the changes in BMD. P values of
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Table 2. Biochemistry
Pamidronate Placebo
Normal
range Pretransplant 1 year Pretransplant 1 year
Serum calcium mmol/L 2.10–2.60 2.41 (0.07) 2.41 (0.05) 2.40 (0.08) 2.39 (0.04)
Serum phosphate mmol/L 0.8–1.4 1.55 (0.12) 1.10 (0.08) 1.71 (0.16) 1.01 (0.08)
PTH pg/ml 10–65 305 (83) 108 (19) 261 (77) 91 (13)
Creatinine lmol/L 44–120 169 (13) 156 (14)
Alkaline phosphatase IU/L 30–130 121 (22) 86 (13) 71 (7) 75 (6)
Aluminium lg/L ,50 27 (8) 19 (8)
Results are expressed as means (SEM).
Table 3. Immunosuppression protocol
Cyclosporine Azathioprine Prednisolone
mg/kg/day
Day 1 10 2 80
Day 2–3 8 2 20
Day 4—week 4 Titrated according to serum levels 200–250 mg/L 2 20
Week 4—week 8 2 15
Week 8—week 12 2 10
less than 0.05 (two tailed) were considered to indicate day 7. They were treated with alphacalcidol to a maxi-
statistical significance. mum dose of 3 mg daily with rapid tapering to zero during
the first month, and both patients were given and toler-
ated the second dose of pamidronate without require-RESULTS
ment for further support of serum calcium concentration.
Twenty-six patients were enrolled and 25 patients (13 No other side effects were encountered.
pamidronate and 12 control) were alive with a function-
ing graft at 12 months and able to complete the study. Immunosuppression
One patient who received pamidronate was undergoing There were no significant differences in the doses of
his third transplant. He suffered intractable rejection and prednisolone, azathioprine and cyclosporine prescribed,
became dialysis dependent after 11 months. Analyses nor of the trough blood cyclosporine concentrations in
have been confined to the 25 patients completing the the two groups of patients over the 12 months. In the
study protocol.
control group, four patients received methylpredniso-
lone for rejection and one required a second course (eachSerum biochemistry
of 3 boli of 500 mg/day). Six patients treated with pami-At the time of transplantation, both groups of patients
dronate received methylprednisolone, and three re-(placebo and treatment) had similar serum PTH concen-
quired a second course.trations (261 6 77 pg/mL vs. 305 6 83 pg/mL, P . 0.7),
blood aluminium concentrations (19 6 8 mg/L vs. 27 6 8 Bone mineral density
mg/L, P . 0.5) and serum alkaline phosphatase concen-
At the femoral neck, significant reduction of BMDtrations (71 6 IU/L vs. 121 6 22 IU/L, P . 0.05; Table 2).
was found in the control patients three months afterAt baseline, neither serum calcium nor serum phosphate
transplantation (1.00 6 0.06 vs. 0.95 6 0.07 g/cm2, mean 6differed between the two groups.
SEM, P , 0.05). Between three months and one year,Sustained and significant falls in serum creatinine and
there were no significant changes in BMD, which re-phosphate concentrations were seen in both groups of
mained significantly below baseline. At 12 months, 10patients. Final values of serum creatinine were 149 6 13
of the 12 patients still manifested a lower femoral neckmmol/L in control and 169 6 16 mmol/L in pamidronate
BMD than at baseline, with a reduction of the meantreated patients. Median PTH decreased to a similar
BMD to 0.92 6 0.06 g/cm2 (P , 0.005 when comparedextent in both groups, but nevertheless remained above
with baseline). These reductions were equivalent to 5%normal in both groups (Table 2).
at three months and 9% at 12 months. No such reductionTwo pamidronate treated patients experienced marked
of mean BMD at the femoral neck was seen in the pami-but asymptomatic reduction of serum calcium concentra-
tion. The nadirs were 1.62 mmol/L and 1.61 mmol/L on dronate treated patients. The mean BMD at the femoral
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Fig. 1. Effect of renal transplantation on
bone mineral density (BMD) at the femoral
neck. Changes in BMD in (A) control patients
and (B) pamidronate treated patients.
neck was 0.94 6 0.06 g/cm2 at baseline versus 0.92 6 a fall of their T score to less than 21.5 (the mean t scores
at baseline were 21.13 6 0.44 and 21.10 6 0.45 at 120.04 g/cm2 at three months and 0.94 6 0.05 at 12 months
(all NS; Fig. 1). Ten of the 13 patients who received months; Tables 4 and 5).
At the lumbar spine, progressive reduction of BMDpamidronate experienced a reduction of BMD at the
femoral neck at three months, but progressive loss of was found in the control patients reaching statistical sig-
nificance by 12 months after transplantation (1.26 6 0.06BMD occurred in only four of the 13 patients.
The T score at the femoral neck showed similar trends. vs. 1.17 6 0.04 g/cm2, P , 0.05, equivalent to a loss of
6.4%). At this site, 9 of the 12 patients manifested BMDAt the time of transplantation the mean T score in the
control group of patients was 20.64 6 0.49 and fell to reduction compared with baseline. In contrast, patients
treated with pamidronate experienced no reduction of21.32 6 0.47 at 12 months. This included four patients
who had a T score less than 21.5 at baseline, increasing lumbar spine BMD at 12 months, although there was a
transient reduction of BMD at three months (Fig. 2).to five at 12 months. In contrast, there was an improve-
ment in the BMD at the femoral neck in two patients who The mean BMD of the pamidronate treated group at 12
months was indistinguishable from that at baseline (1.17 6received pamidronate such that their T score increased to
over 21.5 during the 12 month period after transplanta- 0.06 vs. 1.14 6 0.05 g/cm2, P 5 NS) and eight of the 13
patients lost BMD over this period.tion. No patient in the pamidronate group experienced
Fan et al: Pamidronate and post-transplant bone loss688
Table 4. Control
Lumbar spine Femoral neck
Baseline 12 months P Baseline 12 months P
BMD g/cm2 1.26 (0.06) 1.17 (0.04) ,0.05 1.00 (0.06) 0.92 (0.06) ,0.005
T-score 0.17 (0.52) 20.59 (0.36) ,0.05 20.64 (0.49) 21.32 (0.47) ,0.005
Table 5. Pamidronate
Lumbar spine Femoral neck
Baseline 12 months P Baseline 12 months P
BMD g/cm2 1.17 (0.06) 1.14 (0.05) 0.25 0.94 (0.06) 0.94 (0.05) 0.61
T-score 20.54 (0.52) 20.79 (0.45) 0.27 21.13 (0.44) 21.10 (0.45) 0.84
Fig. 2. Effect of renal transplantation on
BMD at the lumbar spine. Changes in BMD
in (A) control patients and (B) pamidronate
treated patients.
At the lumbar spine, two control patients with a T over the 12 month period, although the four patients
who were below this level remained so.score above 21.5 at the time of transplantation experi-
enced a fall in their T score to below this level at 12 Regression analysis done in both groups separately
and combined showed that the bone loss at both sitesmonths. At 12 months, four of the 12 patients had a T
score below 21.5. In contrast, none of the pamidronate after transplantation was not predicted by age or by the
final level of renal function as judged by serum creatininetreated patients experienced a fall to below this threshold
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concentration at 12 months. Nor was there correlation difficulties of oral bisphosphonates in these complex pa-
tients receiving multiple therapies.between BMD reduction and either baseline PTH, PTH
at 12 months, the change in PTH during the study or The study did not demonstrate any significant detri-
mental effect on renal function. There were more epi-the cumulative steroid dose. Of the variables studied,
only pamidronate treatment predicted a reduction of sodes of cellular rejection in the treatment group, but
the difference was small (5 vs. 9) and not significant.bone loss following transplantation.
There are no data to suggest that bisphosphonates have
immunomodulatory actions that could account for an
DISCUSSION
increased frequency of rejection. The serum half-lives
Adverse skeletal effects of glucocorticoids and mea- of the bisphosphonates are in the order of 0.5 to 2 hours,
sures to prevent them are matters of intense interest [20, and although much of the administered dose remains in
21, 24]. We and others have previously shown that the the skeleton for many years, it is in an inert location and
bone loss rate after renal transplantation is exceptionally unlikely to alter the frequency of rejection.
high [2–5]. In the present study, we have found that the The very rapid early bone loss in these patients, largely
early rapid bone loss that occurs in men during the first abrogated by pamidronate in this study, is probably due
12 months after renal transplantation can be prevented to the combination of relatively high glucocorticoid and
by a simple regimen comprising two intravenous doses cyclosporine exposure and persisting hyperparathyroid-
of pamidronate given at transplantation and again one ism. If cyclosporine is, as suggested by some authors [9, 26],
month later. As judged by the results in the untreated capable of accelerating bone resorption in clinical prac-
patients, without such prophylaxis the skeleton is at risk tice, the combination of reduced formation (glucocorti-
of losing substantial amounts of bone during the first coid induced) and increased resorption (cyclosporine
year: 20.08 6 0.03 g/cm2 (6.4%) at the lumbar spine and and in some patients persistent hyperparathyroidism)
20.09 6 0.02 g/cm2 (8.8%) at the femoral neck in this would have serious skeletal consequences. It is encourag-
instance, and even more in some other studies [1–3]. ing that, in the early months at least, this appears pre-
Guidance on the management of corticosteroid in- ventable by means of the simple anti-resorptive regimen
duced osteoporosis has been provided by the National described here.
Osteoporosis Society and is endorsed by the British Soci- Not addressed by this study is the question of longer
ety for Rheumatology and the Royal Society of Medi- term anti-resorptive or other therapies in renal transplant
cine. They have suggested that a T score less than 21.5 recipients. Although still not established with certainty,
indicates a sufficiently high risk of osteoporotic fractures it is possible that cyclosporine-driven bone resorption
to justify consideration of treatment with a bisphospho- remains inappropriately high, even when the glucocorti-
nate. This is consistent with the European Regulatory coid therapy has been reduced to very low doses or was
Guidelines [25] recently proposed. Adachi et al have withdrawn altogether [8]. Continuing hyperparathyroid-
shown that 15% of patients who are treated with cortico- ism, present in many transplanted patients as confirmed
steroids and have a T score less than 21.44 suffer new in this study, is likely to exacerbate this further. Cyclical
vertebral fractures [17]. In our study, no patients who therapy with clodronate has been shown to induce a gain
received pamidronate at the time of transplantation lost in BMD in patients with documented osteopenia after
BMD at the lumbar spine to below this critical T score. renal transplantation [27], and thus there may well be a
In contrast, two patients in the control group experienced role for longer term bisphosphonate therapy to counter
a fall of BMD at the lumbar spine to less than a T score cyclosporine driven resorption. Conversely, it should be
of 21.5. Similar results were found at the femoral neck; remembered that progressive osteopenia may not occur
no patients in the pamidronate treated group experi- in all patients beyond 24 months of transplantation. Data
enced a fall in BMD such that their T score fell below from Grotz et al suggest that bone density may even
21.5, but one patient in the control group experienced a increase in patients transplanted for more than three
significant decline in BMD. Taken together, these results years, although many of those studied may not have
suggest that a bisphosphonate given at the time of kidney been treated with cyclosporine [6].
transplantation will act as an effective anti-resorptive Calcitonin, vitamin D analogues and calcium supple-
agent and prevent significant bone loss. ments have also been proposed as effective therapeutic
The regimen of two intravenous doses of pamidronate agents to reduce the bone loss associated with glucocorti-
was well tolerated. No discernible side effects were en- coids [24, 28]. Oral calcitriol and calcium administered
countered apart from transient hypocalcemia in two sub- to patients in the first year of starting glucocorticoid was
jects; febrile reactions sometimes associated with pamidro- effective at preventing significant bone loss during the
nate were not seen and were almost certainly prevented first year of treatment. However, this effect was not sus-
by the concomitant steroid therapy. The intravenous reg- tained and bone loss was detected after two years [24].
The efficacy of intranasal calcitonin is unproven. Sodiumimen ensured high compliance and avoided the practical
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tosterone in normal adult males. J Clin Endocrinol Metab 43:622–fluoride is attractive in that it directly stimulates bone
629, 1976
formation [29–31]. However, no convincing data exist 13. Sakakura M, Takebe K, Nakagawa S: Inhibition of luteinizing
hormone secretion induced by synthetic LRH by long-term treat-regarding sodium fluoride treatment in renal transplant
ment with glucocorticoids in human subjects. J Clin Endocrinolrecipients.
Metab 40:774–779, 1975
In conclusion, this study has demonstrated the effec- 14. Hahn TJ: Drug induced disorders of vitamin D and mineral metab-
olism. Clin Endocrinol Metabol 9:107–129, 1980tiveness of two intravenous doses of pamidronate in the
15. Catherwood BD: 1,25-Dihydroxycholecalciferol and glucocorti-prevention of femoral neck and lumbar spine bone loss
coid regulation of adenylate cyclase in an osteoblast-like cell line.
in men during the first 12 months after renal transplanta- J Biol Chem 160:736–743, 1985
16. Chen TL, Feldman D: Glucocorticoid receptors and actions intion. The regimen used was well tolerated, simple to
sub-populations of cultured rat bone cells. Mechanism of dexa-administer and required minimal additional monitoring
methasone potentiation of parathyroid hormone-stimulated cyclic
of the patients during the post-transplant period. Addi- AMP production. J Clin Invest 63:750–758, 1979
17. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A,tional studies are needed in females in whom the need for
Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG,effective countermeasures to post-transplant osteopenia
Tenenhouse A, Chines AA: Intermittent etidronate therapy to
may be even greater. The role of this, or similar, regimens prevent corticosteroid-induced osteoporosis (see comments).
N Engl J Med 337:382–387, 1997in other groups of patients commencing glucocorticoid
18. Sawyer N, Newstead C, Frummond A, Cunningham J: Fast (4-h)therapy remains to be defined, as does the necessary
or slow (24-h) infusions of pamidronate disodium (aminohydroxy-
duration of treatment. The emerging understanding of propylidene diphosphonate (APD)) as single shot treatment of
hypercalcaemia. Bone Miner 9:122–128, 1990the actions of glucocorticoids and cyclosporine on bone
19. Sawyer N, Newstead C, Drummond A, Newland A, Cunning-should help to direct further clinical studies in these high
ham J: One-shot high-dose pamidronate disodium (APD): Effec-
risk patients. tive, simple treatment for hypercalcaemia in haematological malig-
nancy. Clin Lab Haemat 11:179–184, 1989
Reprint requests to Dr. Cunningham, Department of Renal Medicine 20. Gallacher SJ, Fenner JA, Anderson K, Bryden FM, Banham
and Transplantation, The Royal London Hospital, Whitechapel, Lon- SW, Logue FC, Cowan RA, Boyle IT: Intravenous pamidronate
don E1 1BB, England, United Kingdom. in the treatment of osteoporosis associated with corticosteroid
dependent lung disease: An open pilot study. Thorax 47:932–936,
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